Astraea
AI agents that automate clinical trial biometrics and data management
tryastraea.com ↗📍 San Francisco, CA
Verified Data
“Based on YC Spring 2026 batch (launched May 2026), 2-person team, and early pilot customers in pharma. Typical early-stage YC companies with enterprise customers achieve $100K-$500K ARR in first year post-launch.”
“Early stage/Launch phase; currently in production with select pharma teams.”
“Launched May 2026; claimed reduction of biometrics pipeline timeline from months to days.”
Company Profile
Contact
@joshwqngsrStrategic Analysis
Strategy
Targeting pharmaceutical companies with an AI-native platform that fully automates biostatistical processes in clinical trials. Focus on complex Phase II/III trials in oncology and rare diseases where regulatory compliance and speed-to-market are critical. Enterprise-first approach with direct sales to pharma decision makers.
Tactics
Launched through Y Combinator Spring 2026 batch for credibility and network access. Starting with select pilot partnerships in pharma to prove ROI before broader market expansion. Emphasizing regulatory compliance (CDISC, FDA 21 CFR Part 11) as key differentiator in conservative pharma market.
Competitive Positioning
Positioned as the first fully automated solution for clinical trial biometrics, competing against manual processes and legacy statistical software. Differentiates on speed (months to days) and AI-native approach versus traditional biostatistics workflows used by pharma companies.
Marketing Approach
Enterprise sales targeting pharma biometrics teams and clinical operations. Leveraging Y Combinator network and demo day exposure. Focus on ROI messaging around faster drug approval timelines and regulatory compliance automation.
Notable
Y Combinator Spring 2026 batch (YC P26)
🔗 Source ↗Tech Stack
Python
TypeScript
JavaScript
React
Next.jsLLMsMulti-agent AI
AWS
VercelCDISCFDA 21 CFR Part 11Recent News
Related AI Healthcare Companies
Discovery Sources
Signals
“Launched May 2026; claimed reduction of biometrics pipeline timeline from months to days.”
“Early stage/Launch phase; currently in production with select pharma teams.”
Evidence
Agents that accelerate clinical trials.
$500K seed from Y Combinator